Amylin
Amylin, or islet amyloid polypeptide (IAPP), is a 37-residue
IAPP is processed from an 89-residue
Synthesis
ProIAPP consists of 67
(MGILKLQVFLIVLSVALNHLKA) TPIESHQVEKR^ KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTYG^ KR^ NAVEVLKREPLNYLPL.
Regulation
Insofar as both IAPP and insulin are produced by the pancreatic β-cells, impaired β-cell function (due to lipotoxicity and glucotoxicity) will affect both insulin and IAPP production and release.[11]
Insulin and IAPP are regulated by similar factors since they share a common regulatory
Function
Amylin functions as part of the
Amylin's metabolic function is well-characterized as an inhibitor of the appearance of nutrient [especially glucose] in the plasma.[15] It thus functions as a synergistic partner to insulin, with which it is cosecreted from pancreatic beta cells in response to meals. The overall effect is to slow the rate of appearance (Ra) of glucose in the blood after eating; this is accomplished via coordinate slowing down gastric emptying, inhibition of digestive secretion [gastric acid, pancreatic enzymes, and bile ejection], and a resulting reduction in food intake. Appearance of new glucose in the blood is reduced by inhibiting secretion of the gluconeogenic hormone glucagon. These actions, which are mostly carried out via a glucose-sensitive part of the brain stem, the area postrema, may be over-ridden during hypoglycemia. They collectively reduce the total insulin demand.[16]
Amylin also acts in bone metabolism, along with the related peptides
Rodent amylin knockouts do not have a normal reduction of appetite following food consumption.[citation needed] Because it is an amidated peptide, like many neuropeptides, it is believed to be responsible for the effect on appetite.
Structure
The human form of IAPP has the amino acid sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY, with a disulfide bridge between cysteine residues 2 and 7. Both the amidated C-terminus and the disulfide bridge are necessary for the full biological activity of amylin.
History
Before amylin deposition was associated with diabetes, already in 1901, scientists described the phenomenon of "islet hyalinization", which could be found in some cases of diabetes.[23][24] A thorough study of this phenomenon was possible much later. In 1986, the isolation of an aggregate from an insulin-producing tumor was successful, a protein called IAP (Insulinoma Amyloid Peptide) was characterized, and amyloids were isolated from the pancreas of a diabetic patient, but the isolated material was not sufficient for full characterization.[25] This was achieved only a year later by two research teams whose research was a continuation of the work from 1986.[26][27]
Clinical significance
ProIAPP has been linked to Type 2 diabetes and the loss of islet β-cells.[28] Islet amyloid formation, initiated by the aggregation of proIAPP, may contribute to this progressive loss of islet β-cells. It is thought that proIAPP forms the first granules that allow for IAPP to aggregate and form amyloid which may lead to amyloid-induced apoptosis of β-cells.
IAPP is cosecreted with insulin. Insulin resistance in Type 2 diabetes produces a greater demand for insulin production which results in the secretion of proinsulin.[29] ProIAPP is secreted simultaneously, however, the enzymes that convert these precursor molecules into insulin and IAPP, respectively, are not able to keep up with the high levels of secretion, ultimately leading to the accumulation of proIAPP.
In particular, the impaired processing of proIAPP that occurs at the N-terminal cleavage site is a key factor in the initiation of amyloid.
The amyloid formation might be a major mediator of apoptosis, or programmed cell death, in the islet β-cells.[30] Initially, the proIAPP aggregates within secretory vesicles inside the cell. The proIAPP acts as a seed, collecting matured IAPP within the vesicles, forming intracellular amyloid. When the vesicles are released, the amyloid grows as it collects even more IAPP outside the cell. The overall effect is an apoptosis cascade initiated by the influx of ions into the β-cells.
In summary, impaired N-terminal processing of proIAPP is an important factor initiating amyloid formation and β-cell death. These amyloid deposits are pathological characteristics of the pancreas in Type 2 diabetes. However, it is still unclear as to whether amyloid formation is involved in or merely a consequence of type 2 diabetes.[29] Nevertheless, it is clear that amyloid formation reduces working β-cells in patients with Type 2 diabetes. This suggests that repairing proIAPP processing may help to prevent β-cell death, thereby offering hope as a potential therapeutic approach for Type 2 diabetes.
Amyloid deposits deriving from islet amyloid polypeptide (IAPP, or amylin) are commonly found in
A 2008 study reported a synergistic effect for weight loss with
Pharmacology
A synthetic analog of human amylin with proline substitutions in positions 25, 26 and 29, or pramlintide (brand name
Amylin is degraded in part by insulin-degrading enzyme.[36][37] Another long- acting analogue of Amylin is Cagrilintide being developed by Novo Nordisk ( now in the Phase 2 trials with the proposed brand name CagriSema co- formulated with Semaglutide as a once weekly subcutaneous injection ) as a measure to treat type II DM and obesity.
Receptors
There appear to be at least three distinct receptor complexes that amylin binds to with high affinity. All three complexes contain the calcitonin receptor at the core, plus one of three receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.[38]
See also
- carboxypeptidase E
- Pancreatic islets
- peptidylglycine alpha-amidating monooxygenase (PAM)
- Pramlintide
- proprotein convertase 1/3 (PC1/3)
- proprotein convertase 2 (PC2)
- Type II Diabetes
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000121351 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000041681 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Entrez Gene: IAPP islet amyloid polypeptide".
- ^ PMID 10931181.
- ^ "islet amyloid polypeptide precursor [Homo sapiens]". NCBI. (the current NCBI RefSeq)
- ^ PMID 2690069.
- PMID 3053705.
- ^ PMID 15618358.
- PMID 19336687.
- PMID 10933741.
- PMID 21116608.
- PMID 19843871.
- ^ S2CID 35842871.
- S2CID 23236294.
- PMID 18444645.
- PMID 18989933.
- PMID 18989932.
- PMID 17662957.
- PMID 23974296.
- PMID 27693831.
- PMID 19866952.
- ISBN 978-3-662-27815-4.
- PMID 3535798.
- PMID 3317417.
- PMID 3035556.
- PMID 15983213.
- ^ PMID 16873681.
- ^ PMID 16570161.
- S2CID 4244347.
- PMID 18458326.
- ^ {{cite web] |title=Amylin and Takeda halt obesity drug study |url= https://www.pmlive.com/pharma_news/amylin_and_takeda_halt_obesity_drug_study_266050 | work = PMLive |date=17 March 2011}}
- S2CID 33077667.
- ^ "SYMLIN (pramlintide acetate)". Amylin Pharmaceuticals, Inc. 2006. Archived from the original on 13 June 2008. Retrieved 2008-05-28.
- PMID 17051221.
- ^ Suva MA, Patel AM, Sharma N (July 2015). "Role of Amylin in Obesity". Journal of PharmaSciTech. 5: 5–10 – via Google scholar.
- PMID 15494035.
Further reading
- Westermark P, Andersson A, Westermark GT (June 2005). "Is aggregated IAPP a cause of beta-cell failure in transplanted human pancreatic islets?". Current Diabetes Reports. 5 (3): 184–188. S2CID 24682226.
- Höppener JW, Oosterwijk C, Visser-Vernooy HJ, Lips CJ, Jansz HS (December 1992). "Characterization of the human islet amyloid polypeptide/amylin gene transcripts: identification of a new polyadenylation site". Biochemical and Biophysical Research Communications. 189 (3): 1569–1577. PMID 1282806.
- Hubbard JA, Martin SR, Chaplin LC, Bose C, Kelly SM, Price NC (May 1991). "Solution structures of calcitonin-gene-related-peptide analogues of calcitonin-gene-related peptide and amylin". The Biochemical Journal. 275 ( Pt 3) (Pt 3): 785–788. PMID 2039456.
- Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D, et al. (June 1990). "Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans". Diabetes. 39 (6): 752–756. PMID 2189768.
- van Mansfeld AD, Mosselman S, Höppener JW, Zandberg J, van Teeffelen HA, Baas PD, et al. (October 1990). "Islet amyloid polypeptide: structure and upstream sequences of the IAPP gene in rat and man". Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1087 (2): 235–240. PMID 2223885.
- Christmanson L, Rorsman F, Stenman G, Westermark P, Betsholtz C (July 1990). "The human islet amyloid polypeptide (IAPP) gene. Organization, chromosomal localization and functional identification of a promoter region". FEBS Letters. 267 (1): 160–166. S2CID 41096586.
- Clark A, Edwards CA, Ostle LR, Sutton R, Rothbard JB, Morris JF, Turner RC (July 1989). "Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human B-cells and in islets of type-2 diabetic subjects". Cell and Tissue Research. 257 (1): 179–185. S2CID 22046812.
- Nishi M, Sanke T, Seino S, Eddy RL, Fan YS, Byers MG, et al. (November 1989). "Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history". Molecular Endocrinology. 3 (11): 1775–1781. PMID 2608057.
- Mosselman S, Höppener JW, Lips CJ, Jansz HS (April 1989). "The complete islet amyloid polypeptide precursor is encoded by two exons". FEBS Letters. 247 (1): 154–158. S2CID 45121588.
- Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH (June 1987). "Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells". Proceedings of the National Academy of Sciences of the United States of America. 84 (11): 3881–3885. PMID 3035556.
- Mosselman S, Höppener JW, Zandberg J, van Mansfeld AD, Geurts van Kessel AH, Lips CJ, Jansz HS (November 1988). "Islet amyloid polypeptide: identification and chromosomal localization of the human gene". FEBS Letters. 239 (2): 227–232. S2CID 26985644.
- Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (December 1987). "Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients". Proceedings of the National Academy of Sciences of the United States of America. 84 (23): 8628–8632. PMID 3317417.
- Westermark P, Wernstedt C, Wilander E, Sletten K (November 1986). "A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas". Biochemical and Biophysical Research Communications. 140 (3): 827–831. PMID 3535798.
- Höppener JW, Verbeek JS, de Koning EJ, Oosterwijk C, van Hulst KL, Visser-Vernooy HJ, et al. (December 1993). "Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycaemia or hyperinsulinaemia". Diabetologia. 36 (12): 1258–1265. PMID 8307253.
- Lim YA, Ittner LM, Lim YL, Götz J (June 2008). "Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures". FEBS Letters. 582 (15): 2188–2194. S2CID 6201956.
External links
- amylin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- "Amylin Nucleation Site". PDB Entry 1KUW. from the original on 16 April 2008. Retrieved 2008-05-28.
- Human DAP genome location and DAP gene details page in the UCSC Genome Browser.
- Human IAPP genome location and IAPP gene details page in the UCSC Genome Browser.